Correlation Between Nucleus Software and Kilitch Drugs

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Nucleus Software and Kilitch Drugs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nucleus Software and Kilitch Drugs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nucleus Software Exports and Kilitch Drugs Limited, you can compare the effects of market volatilities on Nucleus Software and Kilitch Drugs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nucleus Software with a short position of Kilitch Drugs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nucleus Software and Kilitch Drugs.

Diversification Opportunities for Nucleus Software and Kilitch Drugs

0.62
  Correlation Coefficient

Poor diversification

The 3 months correlation between Nucleus and Kilitch is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Nucleus Software Exports and Kilitch Drugs Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kilitch Drugs Limited and Nucleus Software is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nucleus Software Exports are associated (or correlated) with Kilitch Drugs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kilitch Drugs Limited has no effect on the direction of Nucleus Software i.e., Nucleus Software and Kilitch Drugs go up and down completely randomly.

Pair Corralation between Nucleus Software and Kilitch Drugs

Assuming the 90 days trading horizon Nucleus Software Exports is expected to under-perform the Kilitch Drugs. In addition to that, Nucleus Software is 1.13 times more volatile than Kilitch Drugs Limited. It trades about -0.02 of its total potential returns per unit of risk. Kilitch Drugs Limited is currently generating about 0.0 per unit of volatility. If you would invest  35,015  in Kilitch Drugs Limited on August 31, 2024 and sell it today you would lose (3,950) from holding Kilitch Drugs Limited or give up 11.28% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy99.18%
ValuesDaily Returns

Nucleus Software Exports  vs.  Kilitch Drugs Limited

 Performance 
       Timeline  
Nucleus Software Exports 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nucleus Software Exports has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Kilitch Drugs Limited 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Kilitch Drugs Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Kilitch Drugs is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Nucleus Software and Kilitch Drugs Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Nucleus Software and Kilitch Drugs

The main advantage of trading using opposite Nucleus Software and Kilitch Drugs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nucleus Software position performs unexpectedly, Kilitch Drugs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kilitch Drugs will offset losses from the drop in Kilitch Drugs' long position.
The idea behind Nucleus Software Exports and Kilitch Drugs Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Equity Valuation
Check real value of public entities based on technical and fundamental data
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios